Belgian biotech company Galapagos (Euronext: GLPG) said its drug candidate to treat bowel disease ulcerative colitis failed to achieve efficacy endpoints in mid-stage trials and it will discontinue the trials for that disease.
The company said while the drug candidate, GLPG1205, was well tolerated it did not perform better than the placebo given to another group of patients.
Galapagos said it will evaluate whether the drug candidate will be developed in alternative indications.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze